SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Actinium Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements and the approval process of the Iomab-B BLA [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $75,000 in Actinium between October 31, 2022, and August 2, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Actinium, with a deadline of May 26, 2025, for investors to seek the role of lead plaintiff [3]. - The complaint alleges that Actinium and its executives made false or misleading statements regarding the likelihood of FDA approval for the Iomab-B BLA [5]. Group 2: Stock Performance and Market Reaction - Following the revelation of the need for an additional clinical trial to support the BLA filing, Actinium's stock price dropped significantly, plummeting $3.69, or nearly 60%, to close at $2.48 on August 5, 2024 [6][7]. - The decline in stock price occurred on unusually high trading volume, indicating a strong market reaction to the news [7]. Group 3: Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who is typical of class members and oversees the litigation [8]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [8]. Group 4: Additional Information and Contact - Faruqi & Faruqi encourages anyone with information regarding Actinium's conduct, including whistleblowers and former employees, to contact the firm [9].